Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 10, 2014, Pages 854-858

  Bhagat, Rahul ^a   Zhang, Jean ^b   Farooq, Sidiq ^b   Li, Xiao Yan ^a  

^a ALLERGAN INC   (United States)

^b Oculex   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG IMPLANT; DRUG RELEASE; DRUG SAFETY; FRAGMENTED DEXAMETHASONE INTRAVITREAL IMPLANT; GOOD LABORATORY PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTACT DEXAMETHASONE INTRAVITREAL IMPLANT; INTRAVITREAL IMPLANT; LIQUID CHROMATOGRAPHY; NONHUMAN; TANDEM MASS SPECTROMETRY; VITREOUS BODY; ANIMAL; EYE; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; NEW ZEALAND; RABBIT;

ANIMALS; AQUEOUS HUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXAMETHASONE; DRUG IMPLANTS; EYE; GLUCOCORTICOIDS; INTRAVITREAL INJECTIONS; NEW ZEALAND; RABBITS; TANDEM MASS SPECTROMETRY; VITREOUS BODY;

EID: 84915817496     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0082     Document Type: Article

References (22)

1. Lattanzio, R., Torres Gimeno, A., Battaglia Parodi, M., and Bandello, F. Retinal vein occlusion: current treatment. Ophthalmologica. 225:135-143, 2011.
2. Deobhakta, A., and Chang, L.K. Inflammation in retinal vein occlusion. Int. J. Inflam. 2013:438412, 2013.
3. Robinson, M.R., and Whitcup, S.M. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev. Clin. Pharmacol. 5:629-647, 2012.
4. Hunter, R.S., and Lobo, A.M. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin. Ophthalmol. 5:1613-1621, 2011.
5. Allergan, Inc. Ozurdex (dexamethasone intravitreal implant) prescribing information. Available at www.allergan.com/assets/pdf/ozurdex-pi.pdf (last accessed April 25, 2014).
6. Herrero-Vanrell, R., Cardillo, J.A., and Kuppermann, B.D. Clinical applications of the sustained-release dexametha-sone implant for treatment of macular edema. Clin. Oph-thalmol. 5:139-146, 2011.
7. Ferrini, W., and Ambresin, A. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. Klin. Monbl. Augen-heilkd. 230:423-426, 2013.
8. Kuppermann, B.D., Blumenkranz, M.S., Haller, J.A., et al. Randomized controlled study of an intravitreous dexa-methasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125:309-317, 2007.
9. Haller, J.A., Bandello, F., Belfort Jr., R., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 117:1134-1146 e1133, 2010.
10. Lowder, C., Belfort Jr., R., Lightman, S., et al. Dex-amethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol. 129:545-553, 2011.
11. Naik, R.K., Gelhorn, H., Kowalski, J., et al. Efficacy of dexamethasone intravitreal implant for the treatment of uveitis based on patient-reported vision function outcome measures. Invest. Ophthalmol. Vis. Sci. 51:5875, 2010.
12. Myung, J.S., Aaker, G.D., and Kiss, S. Treatment of non-infectious posterior uveitis with dexamethasone intravitreal implant. Clin. Ophthalmol. 4:1423-1426, 2010.
13. Allergan, Inc. Ozurdex (dexamethasone intravitreal implant) 0.7. Available at www.allergan.com/products/eye- care/ozurdex.htm. (Last accessed April 25, 2014).
14. United States Securities and Exchange Commission. Annual report pursuant to section13 or 15(d) of the Securities Exchange Act of 1934 (for Allergan, Inc.). Available at www.sec.gov/Archives/edgar/data/850693/000085069312000003/agn10-k.htm. (Last accessed April 25, 2014).
15. Boyer, D.S., Yoon, Y.H., Belfort Jr., R., et al. Three-year, randomized, sham-controlled trial of dexamethasone in-travitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904-1914, 2014.
16. Rishi, P., Mathur, G., and Rishi, E. Fractured Ozurdex implant in the vitreous cavity. Indian J. Ophthalmol. 60:337-338, 2012.
17. Roy, R., and Hegde, S. Split Ozurdex implant: a caution. Can. J. Ophthalmol. 48:e15-e16, 2013.
18. Bourgault, S., and Albiani, D. Split Ozurdex implant: a caution. Can. J. Ophthalmol. 48:218-219, 2013.
19. Grubbs, F.E. Procedures for detecting outlying observations in samples. Technometrics. 11:1-21, 1969.
20. Lee, S.S., Hughes, P., Ross, A.D., and Robinson, M.R. Biodegradable implants for sustained drug release in the eye. Pharm. Res. 27:2043-2053, 2010.
21. Chang-Lin, J.E., Attar, M., Acheampong, A.A., et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest. Oph-thalmol. Vis. Sci. 52:80-86, 2011.
22. Chang-Lin, J.E., Burke, J.A., Peng, Q., et al. Pharmacoki-netics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 52:4605-4609, 2011.